Natera is a publicly-traded genetic testing and diagnostics company that specializes in cell-free DNA testing and genetic analysis. The company develops and commercializes molecular testing services, with a particular focus on women's health, oncology, and organ health applications. Natera's proprietary technology platform enables non-invasive genetic testing through advanced bioinformatics and molecular biology techniques.
Founded in 2004, Natera operates in the precision medicine and diagnostics sector, offering tests for prenatal screening, cancer monitoring, and transplant assessment. The company went public in 2015 and has become a significant player in the genetic testing market. Natera's tests are used by healthcare providers to help guide treatment decisions and provide patients with important genetic information. The company continues to expand its testing portfolio and has established partnerships with major healthcare organizations and research institutions.
Natera has received investment from 1 venture capital firm.
Genetic testing and diagnostics company specializing in cell-free DNA testing for women's health, oncology, and organ health.
Natera has received investment from Flint Capital. These venture capital firms and investors provide both capital and strategic support.
Natera operates in the Biotech sector. Genetic testing and diagnostics company specializing in cell-free DNA testing for women's health, oncology, and organ health.
